ℕ𝕖𝕨 ℤ𝕖𝕒𝕝𝕒𝕟𝕕 𝕨𝕒𝕤𝕟’𝕥 𝕤𝕝𝕠𝕨 𝕚𝕟 𝕠𝕣𝕕𝕖𝕣𝕚𝕟𝕘 ℂ𝕠𝕧𝕚𝕕-𝟙𝟡 𝕧𝕒𝕔𝕔𝕚𝕟𝕖𝕤, 𝕤𝕒𝕪𝕤 ℙ𝕗𝕚𝕫𝕖𝕣 𝕓𝕠𝕤𝕤
ℕ𝕖𝕨 ℤ𝕖𝕒𝕝𝕒𝕟𝕕 𝕨𝕒𝕤𝕟’𝕥 𝕤𝕝𝕠𝕨 𝕚𝕟 𝕠𝕣𝕕𝕖𝕣𝕚𝕟𝕘 ℂ𝕠𝕧𝕚𝕕-𝟙𝟡 𝕧𝕒𝕔𝕔𝕚𝕟𝕖𝕤, 𝕤𝕒𝕪𝕤 ℙ𝕗𝕚𝕫𝕖𝕣 𝕓𝕠𝕤𝕤
ℕ𝕖𝕨 ℤ𝕖𝕒𝕝𝕒𝕟𝕕 𝕨𝕒𝕤𝕟’𝕥 𝕤𝕝𝕠𝕨 𝕥𝕠 𝕠𝕣𝕕𝕖𝕣 𝕚𝕥𝕤 𝕕𝕠𝕤𝕖𝕤 𝕠𝕗 𝕥𝕙𝕖 ℙ𝕗𝕚𝕫𝕖𝕣 ℂ𝕠𝕧𝕚𝕕-𝟙𝟡 𝕧𝕒𝕔𝕔𝕚𝕟𝕖, 𝕤𝕒𝕪𝕤 𝕥𝕙𝕖 𝕡𝕙𝕒𝕣𝕞𝕒𝕔𝕖𝕦𝕥𝕚𝕔𝕒𝕝 𝕔𝕠𝕞𝕡𝕒𝕟𝕪’𝕤 𝕞𝕒𝕟𝕒𝕘𝕚𝕟𝕘 𝕕𝕚𝕣𝕖𝕔𝕥𝕠𝕣 𝕗𝕠𝕣 𝔸𝕦𝕤𝕥𝕣𝕒𝕝𝕚𝕒 𝕒𝕟𝕕 ℕ𝕖𝕨 ℤ𝕖𝕒𝕝𝕒𝕟𝕕.
Anne Harris said Pfizer would continue to meet its contractual obligations, as the severity of the pandemic continues to change for each country.
She said the company was constantly in touch with countries about their fast-changing medical needs and vaccine strategies.
“That’s how we are basing this [vaccine distribution]: On the need and what the specific requirements of that country and how they wish to engage with us.”
.
.
As soon as the vaccines were manufactured, they were sent from the factories straight away, she said.
“This is pandemic supply … we aren’t holding inventory within Pfizer. We are providing it to the countries, because we recognise every country is in very different situations.
“We are responding to need and things are going to vary as we move forward through 2021.”
She said New Zealand’s vaccines would come from manufacturers in Europe and the US. Harris said this would ensure large quantities of the vaccine could be created quickly and be of a high quality.
It comes as the European Union late last month threatened to restrict exports of vaccines, including Pfizer’s, outside of the bloc. It was later withdrawn.
Pfizer was committed to meeting its COVAX promises as well, Harris added. The international scheme aimed to ensure global access to the vaccine was equitable, especially for middle- and low-income countries.
As soon as the vaccines were manufactured, they were sent from the factories straight away, she said.
“This is pandemic supply … we aren’t holding inventory within Pfizer. We are providing it to the countries, because we recognise every country is in very different situations.
“We are responding to need and things are going to vary as we move forward through 2021.”
She said New Zealand’s vaccines would come from manufacturers in Europe and the US. Harris said this would ensure large quantities of the vaccine could be created quickly and be of a high quality.
It comes as the European Union late last month threatened to restrict exports of vaccines, including Pfizer’s, outside of the bloc. It was later withdrawn.
Pfizer was committed to meeting its COVAX promises as well, Harris added. The international scheme aimed to ensure global access to the vaccine was equitable, especially for middle- and low-income countries.
.
.
In Covax's first interim distribution forecast, New Zealand could get 250,000 doses of the AstraZeneca-Oxford vaccine before July. But, the alliance said the forecast was non-binding and may change.
The Government bought 1.5 million doses of Pfizer's double-dose Covid-19 vaccine, covering meaning 750,000 New Zealanders will get the vaccine. Five million courses from Janssen have also been ordered.
The Government also secured 10.7 million doses from Novavax, a US vaccine development company, which could vaccinate 5.6 million people. Another 7.6 million doses of the University of Oxford-AstraZeneca vaccine has also been secured, which could cover 3.8 million New Zealanders.
In Covax's first interim distribution forecast, New Zealand could get 250,000 doses of the AstraZeneca-Oxford vaccine before July. But, the alliance said the forecast was non-binding and may change.
The Government bought 1.5 million doses of Pfizer's double-dose Covid-19 vaccine, covering meaning 750,000 New Zealanders will get the vaccine. Five million courses from Janssen have also been ordered.
The Government also secured 10.7 million doses from Novavax, a US vaccine development company, which could vaccinate 5.6 million people. Another 7.6 million doses of the University of Oxford-AstraZeneca vaccine has also been secured, which could cover 3.8 million New Zealanders.
Comments
Post a Comment